Ribociclib
Why in News?
Ribociclib is in the news because the Kerala High Court is examining its very high price and accessibility for breast-cancer patients. On 23 August 2026, the court allowed another breast-cancer patient to join a petition concerning the alleged “exorbitant” price of ribociclib.
Scientific & Clinical Information
- Drug Classification: Ribociclib (sold under the brand name Kisqali or Kryxana in India) is a targeted therapy drug belonging to a class called CDK 4/6 inhibitors.
- Mechanism of Action: It selectively blocks two specific proteins—Cyclin-Dependent Kinase 4 and 6. Overactive CDK 4/6 proteins cause cancer cells to divide rapidly; blocking them stops tumour cell growth and replication.
- Approved Medical Use: It treats HR-positive (Hormone Receptor) and HER2-negative breast cancers, which make up roughly 70–80% of all breast cancer diagnoses.
- Target Populations: It is globally approved for adult female and male patients with advanced or metastatic breast cancer, as well as those with early-stage high-risk cancers to prevent recurrence.
- Dual Administration: Ribociclib is rarely given alone; it is almost always paired with hormone therapies like an aromatase inhibitor or fulvestrant to amplify cancer-fighting efficacy.
- Recurrence Prevention: Clinical studies like the NATALEE trial demonstrated that combining Ribociclib with endocrine therapy reduces the risk of cancer returning by 25% to 30%.
Administration, Storage, and Side Effects
- Standard Dosage: For early-stage breast cancer, the typical dosage is 400 mg daily, while metastatic cases use 600 mg. It is taken orally for 21 consecutive days, followed by a 7-day rest period.
- New Cold-Chain Protocol: Global regulatory reviews by agencies like the U.S. Food and Drug Administration (FDA) mandated that pharmacies store Ribociclib refrigerated until dispensing. Patients can safely keep it at room temperature for up to two months.
- Primary Side Effects: The most common adverse effect is neutropenia (a drop in white blood cell count), which requires regular laboratory blood monitoring.
- Other Adverse Effects: Patients may experience gastrointestinal symptoms (nausea, diarrhea), fatigue, hair thinning, temporary liver test abnormalities, or rare heart complications like QT prolongation.
